ASCO 2023 Highlights

ADCs, NK Cell Engagers, TIGIT, and more updates...

A few insights/notes from the ASCO abstracts that were released late last week.

ADCs Stay Winning

ELEV’s ADC Validating Claudin18.2 Target
The biggest mover from ASCO abstract release seems to be Elevation Oncology ($ELEV) with the stock up 60%. ELEV announced first-in-human data for their antibody-drug conjugate targeting claudin 18.2 in patients with r/r…